Published: 5 August 2020
Author(s): Matteo Toma, Edlira Rrapaj, Paolo Spallarossa, Federico Guerra, Pietro Ameri
Issue: January 2021
Section: Letter to the editor

Prophylaxis of atrial fibrillation (AF)-related cardioembolism in oncology is often challenging [1]. The CHA2DS2-VASc score performs differently according to the presence or absence of cancer, with more thromboembolic and bleeding events occurring in subjects with than without malignancy and a CHA2DS2-VASc score


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.